Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 22, 2023
Identification of a Discrete Diglucuronide of GDC-0810 in Human Plasma after Oral Administration
Chenghong Zhang, Dian Su, Edna F Choo, et al.
Hospital Pediatrics
|
August 24, 2025
Interrater Reliability of Pediatric Respiratory Auscultation Findings
Sriram Ramgopal, Jennifer K Saper, James R Rudloff, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 8, 2015
A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834
Jasleen K Sodhi, Susan Wong, Donald S Kirkpatrick, et al.
Cancer Research Communications
|
November 29, 2023
Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer
Vikram Malhi, Priya Agarwal, Mary R Gates, et al.
Frontiers in Pharmacology
|
May 9, 2022
Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
Haijing Yang, Zhiwei Huang, Yuancheng Chen, et al.
Plos One
|
August 8, 2013
SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition
Jesse E Hanson, Hank La, Emile Plise, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
January 7, 2014
Investigations into the mechanisms of pyridine ring cleavage in vismodegib
S Cyrus Khojasteh, Qin Yue, Shuguang Ma, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 20, 2019
Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model
Yuan Chen, Tamara D Cabalu, Ernesto Callegari, et al.
Oncotarget
|
March 22, 2018
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
John C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
June 22, 2023
Identification of a Discrete Diglucuronide of GDC-0810 in Human Plasma after Oral Administration
Chenghong Zhang, Dian Su, Edna F Choo, et al.
Hospital Pediatrics
|
August 24, 2025
Interrater Reliability of Pediatric Respiratory Auscultation Findings
Sriram Ramgopal, Jennifer K Saper, James R Rudloff, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
April 8, 2015
A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834
Jasleen K Sodhi, Susan Wong, Donald S Kirkpatrick, et al.
Cancer Research Communications
|
November 29, 2023
Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer
Vikram Malhi, Priya Agarwal, Mary R Gates, et al.
Frontiers in Pharmacology
|
May 9, 2022
Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
Haijing Yang, Zhiwei Huang, Yuancheng Chen, et al.
Plos One
|
August 8, 2013
SAHA enhances synaptic function and plasticity in vitro but has limited brain availability in vivo and does not impact cognition
Jesse E Hanson, Hank La, Emile Plise, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
January 7, 2014
Investigations into the mechanisms of pyridine ring cleavage in vismodegib
S Cyrus Khojasteh, Qin Yue, Shuguang Ma, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
June 20, 2019
Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model
Yuan Chen, Tamara D Cabalu, Ernesto Callegari, et al.
Oncotarget
|
March 22, 2018
First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
John C Byrd, Stephen Smith, Nina Wagner-Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2019
A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors
Andrea Varga, Jean-Charles Soria, Antoine Hollebecque, et al.
Page
of 6